experiment 2: factors affecting drug action a. influence of route of administration anacta, klarizza...
Post on 05-Jan-2016
216 Views
Preview:
TRANSCRIPT
Experiment 2: Factors Affecting Drug Experiment 2: Factors Affecting Drug ActionAction
A. INFLUENCE OF ROUTE OF ADMINISTRATION
2A – MedSubsection A2
1
ObjectivesObjectivesGeneral Objectives
◦To determine how the route of administration influences the action of ketamine hydrochloride
2
ObjectivesObjectivesSpecific Objectives
◦To determine the latency (sec) and duration of effect (sec) of ketamine hydrochloride when administered intravenously and intramuscularly
◦ To statistically determine if there is a significant difference between the (a) latencies and (b) durations of effect of ketamine hydrochloride in the IV and IM group
◦To determine the effect of route of administration in the absorption and efficacy of ketamine hydrochloride
3
Definition of terms:Latency/Time to Peak Effect - Time between initial
administration and onset of the maximum expected effect.
Duration of Effect - Length of time peak effect can be expected to last after a single administration of an anesthetic dose.
Righting reflex - A reflex resulting in the body or a body segment tending to regain its former body position when it is displaced.
ESSENTIALS FOR ANIMAL RESEARCH:A PRIMER FOR RESEARCH PERSONNEL
Second EditionMarilyn J. Brown, D.V.M., M.S
http://dcminfo.wustl.edu/education/primer_chap4.htm
4
METHODOLOGYMETHODOLOGY
5
Ketamine hydrochlorideKetamine hydrochloride
Preparation : 50mg/mL
Dosage : 5mg/Kg
2-(O-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride
6
Ketamine hydrochlorideKetamine hydrochloridewater-solublewhite crystallinepKa=7.5commercially available
pharmaceutical form is in aqueous solution
7
Ketamine
2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone
8
Ketamineanesthetic drugblocks the N-methyl-D-aspartate (NMDA)
glutamate receptor = non-competitive NMDA-receptor antagonist
inhibits activation of NMDA receptor by glutamate
reduces presynaptic release of glutamatepotentiates effects of GABA
9
Experimental Animal: Experimental Animal: RabbitRabbit
1
4
2
3
1
4
2
3
1
4
2
3
1
4
2
3
SECTION A
SECTION D
SECTION B
SECTION C10
WeighingWeighing
11
DosageDosage
Dosage of drug=(weight of rabbit)(5mg/kg)(1mL/50mg)
e.g.:(1.5kg)(5mg/kg)(1mL/50mg) = 0.15mL
12
Intramuscularly (IM)Intramuscularly (IM)
1
3
13
Intravenously (IV)Intravenously (IV)
4
2
14
Time of injection
Time the righting reflex was lost
Time the righting reflex was regained
15
Righting reflex“static reflex”bring the body into normal position in
spaceresist forces acting to displace the
body out of normal positionturns a falling animal's body in space
so that its paws or feet are pointed at the ground; hence, returns the animal to sternal recumbency after being placed on its back or side
16
Rabbit with no righting reflex
17
RESULTS and DISCUSSIONRESULTS and DISCUSSION
18
Tabulation of results- Route of AdministrationTabulation of results- Route of Administration
SECTION Latency Duration of Effect
Intramuscular(seconds)
Intravenous(seconds)
Intramuscular(seconds)
Intramuscular(seconds)
A 1 335 11 472 876
2 129 10 322 1112
B 3 170 31 172 371
4 217 30 147 361
C 5 76 7 852 995
6 150 9 517 1357
D 7 232 5 906 880
8 193 9 898 662
Mean 187.75 14 535.75 826.75
SD 72.632207 9.68245837 296.19873 325.552511
Variance 5275.4375 93.75 87733.6875 105984.438
19
Actual ResultsActual Results
L atenc y
0
100
200
300
400
0 1 2 3 4 5 6 7 8 9
ra bbit no.
tim
e (s
ec.)
intramus cular
intravenous
20
Actual ResultsActual Results
0200400600800
1000120014001600
0 1 2 3 4 5 6 7 8 9
tim
e (s
ec.)
rabbit no.
Duration
intramuscular
intravenous
21
Actual ResultsActual ResultsLatency (Mean)
◦Intravenous = 14 seconds◦Intramuscular = 187.75 seconds
Duration (Mean)◦Intravenous = 826.75 seconds◦Intramuscular = 535.75 seconds
22
Hypothesis
Ho: there is no significant difference in the latency/duration between intramuscular and intravenous administration
H1: there is significant difference in the latency/duration between intramuscular and intravenous administration
23
Formula for calculating independent t statisticsTest statistic Its value is used to decide whether or not the null hypothesis should
be rejected in our hypothesis test
= difference between population means
= Pooled standard deviation
24
Latency
Count mean variance Standard deviation
Intramuscular 8 187.75 5275.44 72.63
Intravenous 8 14 93.75 9.68
= √ 5275.44(8-1) + 93.75(8-1) √ 8+8-2 = 51.81
t = (187.75 – 14) – 0
51.81 √1/8+1/8
= 7.00
25
Critical regionSet of values of the test statistic for
which the null hypothesis is rejected in a hypothesis test
df = n1+n2 -2 df = 14Critical region = 1.7613
26
t = 7.00Critical region = 1.76
7.001.76
Fail to reject Ho
Reject Ho
27
Duration
Count mean variance Standard deviation
Intramuscular 8 535.75 87733.69 296.20
Intravenous 8 826.75 105984.44 325.55
Sp= √ (8-1) 87733.69 + (8-1) 105984.44 8+8-2 Sp =311.22
t = (535.75 – 826.75) – 0
311.22√1/8+1/8
= -2.64
28
Duration
1.76
Fail to reject Ho
Reject Ho
t = -2.64
Critical region : 1.7613
29
Actual Results: StatisticsActual Results: StatisticsStudent t test
t test for two independent variablesSignificance level = 0.05
LatencyIntramuscular vs IntravenousP value 0.00017991< 0.05There is significant difference
DurationIntramuscular vs IntravenousP value 0.05115812 > 0.05There is no significant difference
30
Expected resultsExpected resultsIV route has faster onset of action than
IM route
Duration of action is greater in IM than the IV route
31
Intravenous Drug AdministrationIntravenous Drug Administration
Intravenous (IV) [drug administered directly into the bloodstream]
Avoids first pass metabolismRapid and complete absorption
[100% Bioavailability]Fastest rate of drug delivery and
onset of action
32
Intravenous Drug AdministrationIntravenous Drug Administration
Maximal degree of control over drug circulating levels
No way to stop response to drug (no recall)
33
Intramuscular Drug AdministrationIntramuscular Drug Administration
Intramuscular (IM) - Rapid absorption and onset of action• Uptake of drug dependent on blood flow at the
injection site and solubility of the drug.
34
IV versus IM Drug AdministrationIV versus IM Drug Administration
Onset of action is indeed faster in the IV route.
35
DURATION OF ACTION
36
Sources of ErrorHuman Error:
◦The administration of drug was done by different experimenter
◦The time of observation of latency and duration was done by different people
37
CONCLUSIONCONCLUSION
38
IV route has faster onset of action than IM route
The onset of action is dependent on the route of administration
Onset of action
39
Duration of actionDuration of action in the intramuscular
route is dependent on the solubility of the drug
The IM route has a longer duration of action than the IV route
40
ReferencesReferences
Howland, Richard and Mycek, Mary. Lippincott's Illustrated Reviews. Lippincott Williams and Wilkins, 2006.
Katzung, Betram G. Basic and Clinical Pharmacology, 10th ed. The McGraw-Hill Companies, Inc, 2007.
41
THANK YOU!THANK YOU!
42
ToleranceTolerance
Repeated use of ketamineusers can develop a tolerance and/or dependence to the
drug.Rises quickly with regular use and lasts about three days
Can be very high and develop rapidly to the point where after a period of time users will no longer experience the dissociative effects they first began using
Chronic use can cause development of a very high, almost permanent, tolerance to the drug.
43
Ketamine AbsorptionKetamine Absorption
Ketamine is rapidly absorbed when administered through the intramuscular (Tmax 5-15 min), nasal (Tmax 20 min) or oral route (as a solution) (Tmax 30 min).
Bioavailability is low when ketamine is given orally (17%) or rectally (25%). Extensive first pass metabolism in liver and intestine is largely responsible for this effect. Bioavailability after nasal administration is approximately 50% (Malinovsky et al., 1996)
44
Ketamine DistributionKetamine Distribution• Ketamine has a high lipid solubility and low
plasma protein binding (12%), which facilitates rapid transfer across the blood-brain barrier.
Initially it is distributed to highly perfused tissues, including the brain, to achieve levels 4-5 times those in plasma (distribution half-life after i.v. 24 sec.).
CNS effects subside, following redistribution to less well-perfused tissues (re-distribution half-life 2.7 min.).
45
Ketamine MetabolismKetamine MetabolismBiotransformation primarily takes place in the liver.
The most important pathway is N-demethylation to norketamine. When administered orally or rectally, initial plasma norketamine concentrations are higher than those of ketamine are, but the plasma area under the curve (AUC) for norketamine is similar for all routes of administration. Norketamine has one-third the anaesthetic potency of ketamine and has analgesic properties. Norketamine may be metabolised through multiple pathways, but the majority is hydroxylated and subsequently conjugated.
46
Ketamine EliminationKetamine EliminationThe predominant route of elimination
is by liver metabolism. The high extraction rate (0.9) makes ketamine clearance susceptible to factors affecting blood flow. The conjugated hydroxy metabolites are mainly excreted renally. Terminal elimination half-lifes are ranging from 100-200 minutes.
47
top related